
Biomarkers Market by Type (Efficacy, Pharmacodynamics, Predictive), Product & Service (Consumables, Services, Software), Disease, Application - Global Forecast 2024-2030
Description
Biomarkers Market by Type (Efficacy, Pharmacodynamics, Predictive), Product & Service (Consumables, Services, Software), Disease, Application - Global Forecast 2024-2030
The Biomarkers Market size was estimated at USD 60.67 billion in 2023 and expected to reach USD 68.98 billion in 2024, at a CAGR 14.19% to reach USD 153.67 billion by 2030.
Global Biomarkers MarketThe usage of biomarkers is significantly growing to track the presence or progression of diseases and the effectiveness of treatments. These biomarkers are enabled to track and predict patient health conditions, including blood pressure or cholesterol levels. Moreover, cancer biomarkers can be utilized for diagnosis, prognosis and help to estimate cancer stage, subtype, and prediction for treatment response. These biomarkers are essential for the development of personalized or precision medicine. Additionally, these biomarkers are used in drug development processes for various purposes, including identifying the mechanism of action of drugs, drug target selection, enrichment, dose selection, safety assessment, efficacy assessment, and preclinical safety assessment. Furthermore, the need for biomarkers testing is increasing to enhance the monitoring treatment of chronic disease by detecting or confirming the presence of a disease. However, high production costs and difficulties in collecting and preserving samples in biomarkers procedures are hampering the market's growth. Moreover, advancements in the development of cancer prognostic and diagnostic biomarkers are catering to opportunities for market growth.Regional InsightsThe growing cases of chronic diseases across the Americas has increased the need for biomarkers that allow researchers and clinicians to define the status of a disease which further develops novel therapies. The American Cancer Society estimated approximately 1.9 million new diagnosed cancers in 2022, which further expanded the usage of biomarkers for the development of personalized medicine. Additionally, the U.S. and UK governments are heavily investing in the research and development (R&D) in various areas, including tumor profiling, to improve cancer care and develop biomarkers for more effective drugs. In addition, government funding for research and development and increasing the number of clinical trials across Asia-Pacific countries, such as China, India, Vietnam, and South Korea, are expected to create opportunities for the biomarkers market across Asia-Pacific region.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Biomarkers Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biomarkers Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alto Neuroscience,Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BIOINFRA Life Science Inc., BioStarks, BioVision Inc., Charles River Laboratories, Inc., Clarigent Corporation, EKF Diagnostics Holdings PLC, Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Renalytix PLC, Siemens Healthcare GmbH, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc..
Market Segmentation & Coverage
This research report categorizes the Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Efficacy
Pharmacodynamics
Predictive
Prognostic
Safety
Surrogate
Validation
Product & Service
Consumables
Services
Software
Disease
Cancer
Cardiovascular Diseases
Immunological Diseases
Infectious Diseases
Neurological Diseases
Application
Diagnostic
Disease Risk Assessment
Drug Discovery & Development
Personalized Medicine
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Biomarkers Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biomarkers Market?
3. What are the technology trends and regulatory frameworks in the Biomarkers Market?
4. What is the market share of the leading vendors in the Biomarkers Market?
5. Which modes and strategic moves are suitable for entering the Biomarkers Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
189 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Biomarkers Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing usage of biomarkers testing owing to monitor the treatment of chronic disease
- 5.1.1.2. Increasing biomarkers diagnostic application for personalized medicine
- 5.1.1.3. Rising research and development activities in biotechnology and pharmaceutical sector
- 5.1.2. Restraints
- 5.1.2.1. High cost associated with production and lengthy time process for biomarkers development
- 5.1.3. Opportunities
- 5.1.3.1. Recent advancements in the development of prognostic and diagnostic
- biomarkers for cancer treatments
- 5.1.3.2. Integration of advanced technologies to develop biomarkers that provide high accuracy
- 5.1.4. Challenges
- 5.1.4.1. Issues associated with collection and storage of samples in biomarkers
- procedures
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Biomarkers Market, by Type
- 6.1. Introduction
- 6.2. Efficacy
- 6.3. Pharmacodynamics
- 6.4. Predictive
- 6.5. Prognostic
- 6.6. Safety
- 6.7. Surrogate
- 6.8. Validation
- 7. Biomarkers Market, by Product & Service
- 7.1. Introduction
- 7.2. Consumables
- 7.3. Services
- 7.4. Software
- 8. Biomarkers Market, by Disease
- 8.1. Introduction
- 8.2. Cancer
- 8.3. Cardiovascular Diseases
- 8.4. Immunological Diseases
- 8.5. Infectious Diseases
- 8.6. Neurological Diseases
- 9. Biomarkers Market, by Application
- 9.1. Introduction
- 9.2. Diagnostic
- 9.3. Disease Risk Assessment
- 9.4. Drug Discovery & Development
- 9.5. Personalized Medicine
- 10. Americas Biomarkers Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Biomarkers Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Biomarkers Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
- 13.3.1.1. Theralink Acquires Immunotherapy Biomarker Patent From Vanderbilt University
- 13.3.1.2. Mainz Biomed Acquires Entire Intellectual Property Portfolio For Its Colorectal Cancer Diagnostic Test Program
- 13.3.2. Agreement, Collaboration, & Partnership
- 13.3.2.1. ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers
- 13.3.2.2. PrecisionLife Completes Agreement with King’s College London to Enable New Precision Neuroscience Treatments in MND/ALS
- 13.3.2.3. AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
- 13.3.2.4. Vocal Biomarker Agreement Set To Benefit Patients With COPD in India
- 13.3.3. New Product Launch & Enhancement
- 13.3.3.1. Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy
- 13.3.4. Investment & Funding
- 13.3.4.1. Genialis Raises USD 13 Million to Build Clinical Biomarkers that Predict Patient Response
- 13.3.5. Award, Recognition, & Expansion
- 13.3.5.1. Abbott Receives FDA Clearance For First Commercially Available Lab-Based Blood Test To Help Evaluate Concussion
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Alto Neuroscience,Inc.
- 14.1.3. APIS Assay Technologies Limited
- 14.1.4. Augurex Life Sciences Corp
- 14.1.5. Bio-Rad Laboratories, Inc.
- 14.1.6. BioAgilytix
- 14.1.7. Biocrates Life Sciences AG
- 14.1.8. Biofourmis Inc.
- 14.1.9. Biognosys AG
- 14.1.10. BIOINFRA Life Science Inc.
- 14.1.11. BioStarks
- 14.1.12. BioVision Inc.
- 14.1.13. Charles River Laboratories, Inc.
- 14.1.14. Clarigent Corporation
- 14.1.15. EKF Diagnostics Holdings PLC
- 14.1.16. Elo Health, Inc.
- 14.1.17. F. Hoffmann-La Roche, Ltd.
- 14.1.18. Merck KgaA
- 14.1.19. Nightingale Health Plc
- 14.1.20. Owkin Inc.
- 14.1.21. Owlstone Medical Limited
- 14.1.22. PerkinElmer, Inc.
- 14.1.23. Personalis, Inc.
- 14.1.24. Proteomedix AG
- 14.1.25. QIAGEN GmbH
- 14.1.26. Renalytix PLC
- 14.1.27. Siemens Healthcare GmbH
- 14.1.28. Sino Biological Inc.
- 14.1.29. Thermo Fisher Scientific, Inc.
- 14.1.30. VivoSense, Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. BIOMARKERS MARKET RESEARCH PROCESS
- FIGURE 2. BIOMARKERS MARKET SIZE, 2023 VS 2030
- FIGURE 3. BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. BIOMARKERS MARKET DYNAMICS
- FIGURE 7. BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
- FIGURE 10. BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. BIOMARKERS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
- FIGURE 12. BIOMARKERS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 14. BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.